Joint-stock company Grindeks informs that it has established a new anti-cancer final dosage forms\u2019 manufacturing unit, in which 400 thousand lats have been invested. Production processes are organized in accordance with Good Manufacturing Practice and ISO quality standards, which guarantee safety and quality of the produced medications. The new manufacturing unit is equipped with modern and high-performance production facilities to provide convenient, safe, efficient and environmentally friendly manufacturing process. The manufacturing unit is located in the territory of Grindeks, Riga, 53 Krustpils Street.<\/p>\n\n\n\n
Grindeks Chairman of the Council Kirovs Lipmans: \u201cEvery year, the company wisely invests in the development significant amount of money \u2013 about 10% of total turnover. Without such investments further growth of the pharmaceutical company is not possible. In the new manufacturing unit, a number of oncology medications, including our original product and one of the most important products of Grindeks \u2013 Ftorafur \u00ae will be produced. Manufacturing unit\u2019s capacity will be able to provide quantities of packages necessary for the market demand, likewise the new manufacturing unit will be also as a support for Grindeks to take the next step in the expansion of oncology product portfolio. I am sure that in the near future we will be able to talk about a positive return on investment.\u201d<\/p>\n\n\n\n
Grindeks Quality Director Dr. Juris Hmelnickis: \u201cAccording to the legislative and regulatory requirements, cytostatic products \u2013 anti-cancer preparations \u2013 must be produced in separate, specially equipped facilities. The new manufacturing unit is established in compliance with both the Latvian and global norms, which is the most direct proof that the medication is safe and of good quality.\u201d<\/p>\n\n\n\n